Excellent distillation! Importance of research funding for gyn cancers. Need better therapies! Address disparities! #sgomtg #gyncsm pic.twitter.com/Qu7QBNtQ35— Annie Ellis (@Stigetta) March 24, 2018
Research for #ovariancancer #endometrialcancer and #cervicalcancer is grossly underfunded compared to #ProstateCancer - this is a disturbing trend for our patients. #SGOMtg #gyncsm pic.twitter.com/NfqGNF1h1w— Shannon Westin (@ShannonWestin) March 24, 2018
GYN cancers severely under funded compared to other cancers in US. Need to demand more funding to cure gyn cancers! Great presentation by Dr Ryan Spencer. #SGOMtg @SGO_org @UWBadgers #gyncsm pic.twitter.com/BbCbiU6n88— Joshua Garrett Cohen (@JCohenMD) March 24, 2018
OPIOID USE
This makes sense! Tailor your #opioid treatment based on the patient's use while admitted! This can help reduce the # prescribed and potentially impact the #OpioidEpidemic #SGOMtg #gyncsm pic.twitter.com/wRmECFVT6m— Shannon Westin (@ShannonWestin) March 24, 2018
IMPROVED OS OF MINORITY PATIENTS IN CLINICAL TRIALS
Clinical trial enrollment improves overall survival in minority populations with gynecologic cancer. Pts benefit from clinical trials! Great presentation by Dr Patel from MCG @SGO_org @MCG_AUG #SGOMtg pic.twitter.com/nN4SrXWNuM— Joshua Garrett Cohen (@JCohenMD) March 24, 2018
Survival benefit for minorities enrolling on a clinical trial? More reason for trials! #SGOmtg #clinicaltrials pic.twitter.com/i4P6R0iDyn— Erin Stevens (@erinstevensmd) March 24, 2018
EVEROLIMUS/LETROZOLE IN ENDOMETRIAL CANCER
Clinical benefit, PFS and OS were favored in the novel agent combination of everolimus/letrozole in #endometrialcancer - the PFS in chemonaive pts (21mo) appears to out perform Taxol/carboplatin! #SGOMtg #gyncsm— Shannon Westin (@ShannonWestin) March 24, 2018
GOG244 LYMPHEDEMA STUDY
Important update on #Lymphedema incidence in Gyn cancer from the prospective GOG 244 study. There was no difference based on surgical technique. #SGOmtg #gyncsm pic.twitter.com/JQQxtPCqhB— Shannon Westin (@ShannonWestin) March 24, 2018
COST AND PARP MAINTENANCE
Great talk by Dr Liu @CedarsSinai @UCLAJCCC on cost effectiveness of PARPi maintenance #SGOMtg pic.twitter.com/PQlVPHPm2n— Nicole D. Fleming MD (@nicoleflemingmd) March 24, 2018
CHECK POINT INHIBITOR SIDE EFFECTS
Intriguing higher rates of hepatitis & pancreatitis in patients with #ovariancancer treated with immune checkpoint inhibitors reported by Dr. Emily Hinchcliff at #SGOMtg pic.twitter.com/escSdaZYxA— Amir Jazaeri (@AmirJazaeri) March 24, 2018
Learn to manage immunotherapy related side effects now! Celestin Ballroom #SGOMtg pic.twitter.com/VNFQRYNxlJ— Kian Behbakht (@KbKian) March 24, 2018
SENTINEL LYMPH NODE IDENTIFICATION
It was exciting for me to see an advocate - Meg Gaines - present at the meeting. We are making progress.ICG dye to identify SLN in open surgery for Gyn malignancy is superior to blue dye #sgomtg pic.twitter.com/ApzK9b3Vt8— Rick Boulay,MD (@journeycancer) March 24, 2018
Thank you SGO, Amir Jazaeri, Rick Boulay MD, Kian Behbakht, Nicole D. Fleming MD, Shannon Westin, Erin Stevens, Joshua Garrett Cohen, and Annie Ellis for tweeting from the meeting.Presidential Invited Speaker and ovarian cancer survivor Meg Gaines at the SGO Annual Meeting #SGOMtg pic.twitter.com/Js9RLBCV4n— SGO (@SGO_org) March 24, 2018
Dee
Every Day is a Blessing!
No comments:
Post a Comment